Mednet Logo
HomeGastroenterology
Gastroenterology

Gastroenterology

Expert perspectives on IBD, liver disease, motility disorders, and GI diagnostic and therapeutic procedures.

Recent Discussions

Do you refer all of your patients for EGD prior to initiation of atezolizumab/bevacizumab for advanced HCC?

4 Answers

Mednet Member
Mednet Member
Medical Oncology · Geffen School of Medicine at UCLA

Per the trial, this was required within 6 months of starting the study. However, in practice, I don't know that this strict rule would be necessary. For example, what if an EGD was done 10 months ago without varices? I don't think I would feel strongly about this. Similarly, if we could get one shor...

Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?

2
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Zucker School of Medicine at Hofstra / Northwell

The question about switching to another agent for Clostridioides difficile (Cdif) colitis in a patient who tests positive for Cdif but continues to have diarrhea despite multiple days of oral vancomycin treatment does not include any information regarding the clinical status of the patient, the pres...

What is your approach to the management of chronic GI bleeding from AVMs in an elderly patient on DOAC for atrial fibrillation?

6
7 Answers

Mednet Member
Mednet Member
Cardiology · University of California - Davis Health

I would definitely strongly consider the left atrial appendage occlusion device in these patients. While usually these devices (such as Watchman) do require anticoagulation for about 45 days until the device has an endothelial layer form on it (we usually confirm with a CT scan or TEE), there are so...

If a young patient with biopsy proven EOE is doing well on bid PPI, when would you consider switching to Dupixent in order to precent long term complications such as strictures?

1
1 Answers

Mednet Member
Mednet Member
Gastroenterology · Harvard Medical School

If the patient is in proven histologic remission on PPI and the symptoms are well-controlled, then the patient has PPI-responsive EoE and can stay on PPI as maintenance therapy. There is no indication for switching to Dupixent in this scenario except for patient preference. There is no current evide...

Would you avoid risankizumab in a patient with stricturing Crohn’s complicated by granulomatous bronchiolitis with stenosis who had to stop ustekinumab due to hemoptysis?

1
2 Answers

Mednet Member
Mednet Member
Gastroenterology · Icahn School of Medicine at Mount Sinai

Unless there had been a rapid and dramatic beneficial response of the Crohn’s disease to ustekinumab, I would have little appetite for trying another IL-blocker. A different mechanism, like JAK, might be worth trying, but the serious pulmonary complication probably warrants steroid therapy. One coul...

How do you decide between anticoagulation or portal vein recanalization in a patient with portal vein thrombosis?

1
1 Answers

Mednet Member
Mednet Member
Hepatology · Northwestern

It depends on cirrhotic vs non-cirrhotic. For cirrhotic, best to reference the AASLD 2020 guidance here - Northup et al., PMID 33219529.For non-cirrhotic: important to determine the etiology as well as evaluate for a hypercoagulable state, including checking for JAK2 and CALR.If acute and non-occlus...

How do you explain the use of an AI scribe to patients the first time it is used in their care?

9
5 Answers

Mednet Member
Mednet Member
Psychiatry · Private Practice

In residency, we had to get patient permission to videotape sessions and allow our supervisors to watch sessions from behind a one-way mirror. If I were to use a scribe, especially an AI scribe, or if I were audio or video taping the sessions, I would definitely want to get a patient’s approval. I d...

Would you use upfront atezo/bev in a patient with HCC and untreated hepatitis?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Geffen School of Medicine at UCLA

Yes. I would not have concerns. For HBV, I would start treatment before or simultaneously. Studies have varied by protocol about the HBV viral load being under 500 or 100 but it is not clear this matters. There have not been flairs reported. In regards to HCV, again, not an issue for me.

For patients with HCC that have stable disease on immunotherapy alone, would you consider adding bevacizumab at the time of disease progression and continue immunotherapy?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

Yes, this is applicable to patients who are on single agent immunotherapy, since the atezo/bev combination carries different mechanism of synergistic potential than single agent immunotherapy. Notably, currently approved second line agents are indicated after progression on sorafenib, however, curre...

In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?

1
5 Answers

Mednet Member
Mednet Member
Hematology · Gundersen Health

Oral iron can often be effective in iron deficiency, as long as absorption is intact. If you are concerned about absorption, performing an oral iron challenge can be useful in allowing you to avoid long trials of oral iron that will be ineffective. Simply check an iron panel at baseline, then admini...